Evidence map›Paper›PMID 32523944›Full record

ArticleFrontiers in bioengineering and biotechnology2020

Personalized Graphene Oxide-Protein Corona in the Human Plasma of Pancreatic Cancer Patients.

Riccardo Di Santo, Luca Digiacomo, Erica Quagliarini, Anna Laura Capriotti, Aldo Laganà, Riccardo Zenezini Chiozzi, Damiano Caputo, Chiara Cascone, Roberto Coppola, Daniela Pozzi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Riccardo Di SantoNanodelivery Lab, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Luca DigiacomoNanodelivery Lab, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Erica QuagliariniDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
Anna Laura CapriottiDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
Aldo LaganàDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
Riccardo Zenezini ChiozziBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
Damiano CaputoGeneral Surgery Unit, University Campus Bio-Medico di Roma, Rome, Italy.
Chiara CasconeGeneral Surgery Unit, University Campus Bio-Medico di Roma, Rome, Italy.
Roberto CoppolaGeneral Surgery Unit, University Campus Bio-Medico di Roma, Rome, Italy.
Daniela PozziNanodelivery Lab, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Giulio CaraccioloNanodelivery Lab, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITUniversità Campus Bio-Medico · ITUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The protein corona (PC) that forms around nanomaterials upon exposure to human biofluids (e.g., serum, plasma, cerebral spinal fluid etc.) is personalized, i.e., it depends on alterations of the human proteome as those occurring in several cancer types. This may relevant for early cancer detection when changes in concentration of typical biomarkers are often too low to be detected by blood tests. Among nanomaterials under development for

Indexed as

graphene oxidenanoparticlespancreatic ductal adenocarcinomaprecision medicineprotein corona

Identifiers

PMID32523944
PMCPMC7261887
OpenAlexW3026457934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.